Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone.
Life-threatening bleeding can occur in non-hemophiliacs with factor VIII inhibitor and is difficult to control. Various methods have been used to suppress the inhibitor. Since 1993 we treated 6 non-hemophilic patients with factor VIII inhibitor with cyclophosphamide, vincristine, and prednisone (CVP) every 3-4 weeks. Five had complete response with disappearance of factor VIII inhibitor and normalization of factor VIII after 1 to 7 cycles of CVP. One patient did not respond after 4 cycles of CVP; mitoxantrone was added to additional two cycles of CVP, and the inhibitor disappeared.
Lian
Eric C-Y
EC
Division of Hematology/Oncology, University of Miami School of Medicine/Sylvester Cancer Center/Veterans Affairs Medical Center, Miami, Florida 33136, USA. elian@med.miami.edu
Villar
Mary Jo
MJ
Noy
Lionel I
LI
Ruiz-Dayao
Zoneddy
Z
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005169:Factor VIII / Q000032:analysis / Q000276:immunology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D014750:Vincristine; D003520:Cyclophosphamide; D005169:Factor VIII; D011241:Prednisone